Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13983476 | 0.94 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL12180265 | 0.89 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL9925249 | 0.89 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1 | |
| SCHEMBL12045810 | 0.84 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1 | |
| SCHEMBL806553 | 0.83 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL13983147 | 0.83 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1 | |
| SCHEMBL419802 | 0.78 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL13983472 | 0.78 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1 | |
| SCHEMBL9925250 | 0.77 | GOT1 (0.36) | HSP90AA1 | |
| SCHEMBL14933295 | 0.77 | BRD4 (0.38) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013067162-A1 | CANCER THERAPY USING A COMBINATION OF HSP90 INHIBITORS WITH TOPOISOMERASE I INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012116061-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH RADIOTHERAPY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012078757-A2 | COMBINATION BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012037072-A1 | HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |